146 related articles for article (PubMed ID: 37922835)
1. CLN2 disease resulting from a novel homozygous deep intronic splice variant in TPP1 discovered using long-read sequencing.
Steigerwald C; Borsuk J; Pappas J; Galey M; Scott A; Devaney JM; Miller DE; Abreu NJ
Mol Genet Metab; 2023 Dec; 140(4):107713. PubMed ID: 37922835
[TBL] [Abstract][Full Text] [Related]
2. A novel CLN2/TPP1 mutation in a Chinese patient with late infantile neuronal ceroid lipofuscinosis.
Wang YL; Zeng ZY; Song XW; Hao ZF; Shi YW; Tang B; Chen SQ; Gao MM; Di W; Long YS; Yi YH; Liao WP
Neurogenetics; 2011 Feb; 12(1):93-5. PubMed ID: 20820830
[No Abstract] [Full Text] [Related]
3. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis.
Fietz M; AlSayed M; Burke D; Cohen-Pfeffer J; Cooper JD; Dvořáková L; Giugliani R; Izzo E; Jahnová H; Lukacs Z; Mole SE; Noher de Halac I; Pearce DA; Poupetova H; Schulz A; Specchio N; Xin W; Miller N
Mol Genet Metab; 2016 Sep; 119(1-2):160-7. PubMed ID: 27553878
[TBL] [Abstract][Full Text] [Related]
4. Cynomolgus macaque model of neuronal ceroid lipofuscinosis type 2 disease.
Munesue Y; Ageyama N; Kimura N; Takahashi I; Nakayama S; Okabayashi S; Katakai Y; Koie H; Yagami KI; Ishii K; Tamaoka A; Yasutomi Y; Shimozawa N
Exp Neurol; 2023 May; 363():114381. PubMed ID: 36918063
[TBL] [Abstract][Full Text] [Related]
5. Autosomal recessive spinocerebellar ataxia 7 (SCAR7) is caused by variants in TPP1, the gene involved in classic late-infantile neuronal ceroid lipofuscinosis 2 disease (CLN2 disease).
Sun Y; Almomani R; Breedveld GJ; Santen GW; Aten E; Lefeber DJ; Hoff JI; Brusse E; Verheijen FW; Verdijk RM; Kriek M; Oostra B; Breuning MH; Losekoot M; den Dunnen JT; van de Warrenburg BP; Maat-Kievit AJ
Hum Mutat; 2013 May; 34(5):706-13. PubMed ID: 23418007
[TBL] [Abstract][Full Text] [Related]
6. Multifocal retinopathy in Dachshunds with CLN2 neuronal ceroid lipofuscinosis.
Whiting RE; Pearce JW; Castaner LJ; Jensen CA; Katz RJ; Gilliam DH; Katz ML
Exp Eye Res; 2015 May; 134():123-32. PubMed ID: 25697710
[TBL] [Abstract][Full Text] [Related]
7. Aberrant splicing and transcriptional activity of TPP1 result in CLN2-like disorder.
Helman G; Taylor LE; Walkiewicz M; Le Moing M; Eggers S; Yaplito-Lee J; Fuller M; Dabscheck G; Rodriguez-Casero V; White SM; Simons C
Eur J Med Genet; 2021 Aug; 64(8):104259. PubMed ID: 34126256
[TBL] [Abstract][Full Text] [Related]
8. Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease.
Gardner E; Bailey M; Schulz A; Aristorena M; Miller N; Mole SE
Hum Mutat; 2019 Nov; 40(11):1924-1938. PubMed ID: 31283065
[TBL] [Abstract][Full Text] [Related]
9. Intraventricular Cerliponase Alfa Treatment in a Patient with Advanced Neuronal Ceroid Lipofuscinosis Type 2.
Nakashima S; Hamada M; Kimura T; Tanifuji S; Takahashi A; Yashita D; Kakimoto Y; Matsukawa T; Ishiura H; Toda T
Intern Med; 2024 Jun; 63(12):1807-1812. PubMed ID: 37926545
[TBL] [Abstract][Full Text] [Related]
10. A novel CLN2/TPP1 mutation in a patient with late infantile neuronal ceroid lipofuscinosis.
Yu F; Liu XM; Chen YH; Zhang SQ; Wang K
Neurol Sci; 2015 Oct; 36(10):1917-9. PubMed ID: 26032578
[No Abstract] [Full Text] [Related]
11. Neuronal ceroid lipofuscinosis type CLN2: a new rationale for the construction of phenotypic subgroups based on a survey of 25 cases in South America.
Kohan R; Carabelos MN; Xin W; Sims K; Guelbert N; Cismondi IA; Pons P; Alonso GI; Troncoso M; Witting S; Pearce DA; Dodelson de Kremer R; Oller-Ramírez AM; Noher de Halac I
Gene; 2013 Mar; 516(1):114-21. PubMed ID: 23266810
[TBL] [Abstract][Full Text] [Related]
12. Homozygous missense TPP1 mutation associated with mild late infantile neuronal ceroid lipofuscinosis and the genotype-phenotype correlation.
Chen ZR; Liu DT; Meng H; Liu L; Bian WJ; Liu XR; Zhu WW; He Y; Wang J; Tang B; Su T; Yi YH
Seizure; 2019 Jul; 69():180-185. PubMed ID: 31059981
[TBL] [Abstract][Full Text] [Related]
13. Targeted re-sequencing for early diagnosis of genetic causes of childhood epilepsy: the Italian experience from the 'beyond epilepsy' project.
Amadori E; Scala M; Cereda GS; Vari MS; Marchese F; Di Pisa V; Mancardi MM; Giacomini T; Siri L; Vercellino F; Serino D; Orsini A; Bonuccelli A; Bagnasco I; Papa A; Minetti C; Cordelli DM; Striano P
Ital J Pediatr; 2020 Jul; 46(1):92. PubMed ID: 32631363
[TBL] [Abstract][Full Text] [Related]
14. Gene symbol: TPP1. Disease: Neuronal Ceroid Lipofuscinosis, late infantile.
Kohan R; Muller VJ; Fietz MJ; Cismondi AI; Oller Ramírez AM; Halac IN
Hum Genet; 2008 Jun; 123(5):553. PubMed ID: 20960655
[No Abstract] [Full Text] [Related]
15. Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease).
Katz ML; Coates JR; Sibigtroth CM; Taylor JD; Carpentier M; Young WM; Wininger FA; Kennedy D; Vuillemenot BR; O'Neill CA
J Neurosci Res; 2014 Nov; 92(11):1591-8. PubMed ID: 24938720
[TBL] [Abstract][Full Text] [Related]
16. Batten disease: biochemical and molecular characterization revealing novel PPT1 and TPP1 gene mutations in Indian patients.
Sheth J; Mistri M; Bhavsar R; Pancholi D; Kamate M; Gupta N; Kabra M; Mehta S; Nampoothiri S; Thakker A; Jain V; Shah R; Sheth F
BMC Neurol; 2018 Dec; 18(1):203. PubMed ID: 30541466
[TBL] [Abstract][Full Text] [Related]
17. A needle in a haystack? The impact of a targeted epilepsy gene panel in the identification of a treatable but rapidly progressive metabolic epilepsy: CLN2 disease.
Lourenço CM; Sallum JMF; Pereira AM; Girotto PN; Kok F; Vilela DRF; Barron E; Pessoa A; Oliveira BM
Arq Neuropsiquiatr; 2024 May; 82(5):1-8. PubMed ID: 38763144
[TBL] [Abstract][Full Text] [Related]
18. Protracted late infantile ceroid lipofuscinosis due to TPP1 mutations: Clinical, molecular and biochemical characterization in three sibs.
Di Giacopo R; Cianetti L; Caputo V; La Torraca I; Piemonte F; Ciolfi A; Petrucci S; Carta C; Mariotti P; Leuzzi V; Valente EM; D'Amico A; Bentivoglio A; Bertini E; Tartaglia M; Zampino G
J Neurol Sci; 2015 Sep; 356(1-2):65-71. PubMed ID: 26143525
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of tripeptidyl-peptidase 1 by 3-hydroxy-(2,2)-dimethyl butyrate, a brain endogenous ligand of PPARα: Implications for late-infantile Batten disease therapy.
Chakrabarti S; Chandra S; Roy A; Dasarathi S; Kundu M; Pahan K
Neurobiol Dis; 2019 Jul; 127():362-373. PubMed ID: 30928643
[TBL] [Abstract][Full Text] [Related]
20. A zebrafish model of CLN2 disease is deficient in tripeptidyl peptidase 1 and displays progressive neurodegeneration accompanied by a reduction in proliferation.
Mahmood F; Fu S; Cooke J; Wilson SW; Cooper JD; Russell C
Brain; 2013 May; 136(Pt 5):1488-507. PubMed ID: 23587805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]